EUVIMEDEUVIMED entdecken
Crossref

RUVBL1 supports TIP60-associated proteasome adaptation and temozolomide resistance in glioblastoma

Yang Kong, Wei Zhu, Kun Xue, Ya Gao, Caifeng Ma, Shuo Tang, Wei Sun, Guangqiang Cui, Xinghan Tian, Haiying Wang

Cellular Signalling · 2026

DOI: 10.1016/j.cellsig.2026.112795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Yang Kong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Rehabilitation, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Drug Resistance, Neoplasm, Proteasome Endopeptidase Complex. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Qingdao University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glioblastoma (GBM) remains highly lethal, and resistance to temozolomide (TMZ) is a major barrier to durable therapeutic response. Although MGMT-mediated DNA repair is a well-established mechanism of TMZ resistance, how GBM cells maintain proteostasis under sustained chemotherapy stress remains less defined. METHODS: We analyzed RUVBL1 expression and clinical relevance in glioma datasets from TCGA and validation cohorts. Functional studies were performed using RUVBL1 knockdown, TMZ-resistant GBM cells, proteasome activity assays, protein aggregation analysis, ER stress assessment, and rescue experiments with wild-type or ATPase-deficient RUVBL1 constructs. The therapeutic effect of pharmacological RUVBL1/2 ATPase inhibition was evaluated using CB-6644 in combination with TMZ in vitro and in orthotopic xenograft models. RESULTS: RUVBL1 was upregulated in gliomas and associated with higher tumor grade, aggressive molecular features, and poorer patient survival. In TMZ-resistant GBM cells, RUVBL1 supported elevated proteasome-related gene expression and proteasome activity. RUVBL1 knockdown impaired this adaptive proteostasis program, leading to protein aggregate accumulation, ubiquitinated protein buildup, ER stress activation, and enhanced TMZ-induced apoptosis. Mechanistically, RUVBL1 interacted with TIP60 and was associated with maintenance of H3K9/K27 acetylation, NRF1-related proteasome gene expression, and proteasome activity. Rescue experiments showed that wild-type RUVBL1, but not the ATPase-deficient D302N mutant, restored these effects, indicating the requirement of RUVBL1 ATPase activity. Pharmacological inhibition of the RUVBL1/2 ATPase complex by CB-6644 sensitized TMZ-resistant GBM cells to TMZ. In orthotopic xenograft models, CB-6644 combined with TMZ reduced tumor growth and extended survival without obvious systemic toxicity. CONCLUSIONS: RUVBL1 contributes to TMZ resistance in GBM by supporting TIP60-associated proteasome adaptation and proteostasis maintenance under chemotherapy stress. Targeting the RUVBL1/2 ATPase complex may weaken this adaptive program and enhance TMZ efficacy, suggesting a proteostasis-related therapeutic vulnerability in TMZ-resistant GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaDrug Resistance, NeoplasmProteasome Endopeptidase ComplexDNA HelicasesATPases Associated with Diverse Cellular ActivitiesLysine Acetyltransferase 5Carrier ProteinsBrain NeoplasmsHumansAnimalsCell Line, TumorMiceAntineoplastic Agents, AlkylatingMice, Nude

Stichwörter der Autor:innen

ER stressGlioblastomaProteasomeRUVBL1TIP60Temozolomide resistance

Substanzen

TemozolomideProteasome Endopeptidase ComplexDNA HelicasesATPases Associated with Diverse Cellular ActivitiesRUVBL1 protein, humanLysine Acetyltransferase 5KAT5 protein, humanCarrier ProteinsAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Critical Care Rehabilitation, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
  • Department of Neurosurgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
  • Department of Neurosurgery, Yantaishan Hospital, Yantai, China.
  • Department of Critical Care Rehabilitation, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China; The Second Clinical Medical School, Shandong Medical and Pharmaceutical University, Yantai, Ch…
  • Department of Critical Care Rehabilitation, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China; School of Medicine, Qingdao University, Qingdao, China.
  • Department of Anesthesiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China. Electronic address: 418273519@qq.com.

Förderung

  • Natural Science Foundation of Shandong Province
  • Qingdao University

Zitieren

APA

Kong, Y., Zhu, W., Xue, K., Gao, Y., Ma, C., Tang, S., Sun, W., Cui, G., Tian, X., & Wang, H. (2026). RUVBL1 supports TIP60-associated proteasome adaptation and temozolomide resistance in glioblastoma. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2026.112795

Vancouver

Kong Y, Zhu W, Xue K, Gao Y, Ma C, Tang S, et al. RUVBL1 supports TIP60-associated proteasome adaptation and temozolomide resistance in glioblastoma. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2026.112795

BibTeX
@article{Kong2026,
  author = {Kong, Yang and Zhu, Wei and Xue, Kun and Gao, Ya and Ma, Caifeng and Tang, Shuo and Sun, Wei and Cui, Guangqiang and Tian, Xinghan and Wang, Haiying},
  title = {RUVBL1 supports TIP60-associated proteasome adaptation and temozolomide resistance in glioblastoma},
  journal = {Cellular Signalling},
  year = {2026},
  doi = {10.1016/j.cellsig.2026.112795}
}
Kostenlos starten →